STOCK TITAN

RLFTD - RLFTD STOCK NEWS

Welcome to our dedicated news page for RLFTD (Ticker: RLFTD), a resource for investors and traders seeking the latest updates and insights on RLFTD.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RLFTD's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RLFTD's position in the market.

Rhea-AI Summary
RELIEF THERAPEUTICS reports financial results for H1 2023, positive corporate update
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Acer Therapeutics buys Relief Therapeutics' stake in OLPRUVA worldwide, excluding geographical Europe, providing an upfront payment of $10 million in cash to Relief Therapeutics with the potential for an additional $46.5 million in milestone and royalty payments. The transition to a revenue-based royalty stream model is expected to deliver earlier returns and enhanced predictability to Relief Therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Relief Therapeutics announces the results of its Annual General Meeting (AGM) of shareholders. Certain proposed items by the board of directors did not receive majority approval, possibly due to differences in opinion on the future development of the company. The rejected proposals will be reviewed and analyzed. The AGM approved the annual report and financial statements for 2022, but denied discharge to the board of directors and executive committee for their activities in 2022. The capital band and conditional share capital remain unchanged. Most proposed amendments to the Articles of Association were approved, except for compensation-related amendments. Compensation proposals for board members and the executive committee were rejected. Existing board members were re-elected, including Dr. Raghuram Selvaraju as chairman. The nomination and compensation committee, independent voting rights representative, and auditors were also re-elected.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.45%
Tags
none
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.33%
Tags
management
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.03%
Tags
none
RLFTD

OTC:RLFTD

RLFTD Rankings

RLFTD Stock Data

44.94M
7.53M
Biotechnology
Healthcare
Link
Switzerland
Geneva